Ratings Hualan Biological Vaccine Inc.

Equities

301207

CNE1000058J9

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
19.14 ^CNY	-0.36%		-5.34%	-31.15%

Apr. 25	Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
With a P/E ratio at 11.06 for the current year and 9.19 for next year, earnings multiples are highly attractive compared with competitors.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HUALAN BIOLOGICAL VACCINE INC.	-31.15%	1.59B	-
CSL LIMITED	-2.95%	90.75B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	39.03B	A-
BIOGEN INC.	-17.08%	31.85B	B-
UCB	+61.22%	26.26B	A
BIOMARIN PHARMACEUTICAL INC.	-22.15%	14.13B	C
INCYTE CORPORATION	-9.36%	12.87B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.39%	11.6B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.06%	10.91B	B
SWEDISH ORPHAN BIOVITRUM AB	+2.17%	8.89B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes